Overview

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to investigate how quickly and to what extent YM178 is absorbed and eliminated from the body, and how well it is tolerated, when given in three different tablet formulations (sustained release) once a day with and without food, and to compare the results with the profile of the YM178 immediate release formulation taken twice daily without food.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

Mirabegron